Followers | 125 |
Posts | 14625 |
Boards Moderated | 2 |
Alias Born | 04/26/2013 |
![](https://investorshub.advfn.com/uicon/395980.png?cb=1699265709)
Saturday, September 30, 2023 7:24:26 AM
***FOLLOW FOR ALERTS***
Recent OKYO News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/11/2024 11:00:09 AM
- OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101 • GlobeNewswire Inc. • 07/11/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/10/2024 11:00:33 AM
- OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease • GlobeNewswire Inc. • 07/10/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/10/2024 10:50:29 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/08/2024 11:00:21 AM
- OKYO Pharma Announces Participation in May 2024 Investor Conferences • GlobeNewswire Inc. • 05/08/2024 11:00:00 AM
- OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO) • GlobeNewswire Inc. • 04/30/2024 11:00:00 AM
- OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024 • GlobeNewswire Inc. • 04/08/2024 11:00:00 PM
- OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery • GlobeNewswire Inc. • 04/02/2024 11:00:00 AM
- OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101 • GlobeNewswire Inc. • 03/22/2024 11:00:00 AM
- OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial • GlobeNewswire Inc. • 03/21/2024 11:00:00 AM
- OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event • GlobeNewswire Inc. • 03/20/2024 11:00:00 AM
- OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain • InvestorsHub NewsWire • 02/09/2024 12:36:59 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/09/2024 12:00:36 PM
- OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain • GlobeNewswire Inc. • 02/09/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/31/2024 12:00:20 PM
- OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board • GlobeNewswire Inc. • 01/31/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/08/2024 12:00:33 PM
- OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye Disease • GlobeNewswire Inc. • 01/08/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/05/2024 02:30:06 PM
- OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024 • GlobeNewswire Inc. • 01/05/2024 02:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/21/2023 12:35:34 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/20/2023 10:30:30 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/18/2023 09:56:45 PM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM